Category
6 articles
Patients tell us they can discuss dosage with a pharmacist more easily than with their own families. This opinion piece examines the stigma surrounding GLP-1 medication in Britain — and why silence can carry its own risks.
GLP-1 treatment doesn't just change appetite — it changes the contents of the trolley. We examine how UK patients' shopping habits shift on prescription weight-loss medication, what the new basket looks like, and how to keep it nutritious and affordable from Tesco to Aldi.
Clinical trial data, MHRA Yellow Card reports and patient forums all tell a similar story: the first three months of GLP-1 treatment follow a predictable pattern of side effects. We rank them by frequency and severity, and explain when self-management is safe and when you should contact your prescriber.
The sticker price of Wegovy is only the beginning. We break down a full year of treatment across NHS, private clinic and online pharmacy routes — including the consultations and blood tests that quietly inflate the bill — and assess where paying extra genuinely buys better care.
Stopping a GLP-1 injection does not simply end treatment — it begins a physiological shift that many patients are unprepared for. Here is what the evidence says about weight regain, and the maintenance strategies UK clinicians now recommend.
The UK's online weight-loss market is booming, and not every provider deserves your trust — or your payment details. Here are seven questions that separate legitimate telehealth clinics from the operations that put patients at risk.